TauRx Therapeutics Selects BioClinica For eClinical And Imaging Solutions

  TauRx Therapeutics Selects BioClinica For eClinical And Imaging Solutions

      - Global Experience, Flexibility, and Speed to Support Innovative
                     Neurodegenerative Disease Research -

Business Wire

NEWTOWN, Pa. -- November 05, 2012

BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial
management solutions, today announced that TauRx Therapeutics has signed
agreements with BioClinica to use Trident IWR/IVR and Imaging Core Lab (ICL)
solutions to support its upcoming Phase III clinical trials. TauRx, a
Singapore-based company, focuses its research on therapies and diagnostics for
the treatment of Alzheimer's disease and other neurodegenerative disorders.
With primary research facilities in Aberdeen in the United Kingdom, TauRx is
the latest European customer to select BioClinica for both Imaging and
eClinical offerings.

TauRx has selected Trident IWR/IVR for a series of expanded trials for its
pipeline of neurology treatment candidates. “TauRx chose Trident IWR to reduce
the lead time and effort needed to prepare for our studies, while supporting
all of our randomization and clinical supplies tracking requirements,” said
Dr. Jiri Hardlund, Chief Medical Officer for TauRx. “When we investigated the
available technologies, it was clear that Trident offered clear advantages for
our trials’ requirements.”

A separate selection team evaluated imaging solutions, and also selected
BioClinica for its Imaging Core Lab solutions for processing MRI data. “MRI
imaging represents a critical eligibility and safety component of our clinical
studies,” said Dr. Diane Downie, Global Logistics and Support Lead at TauRx.
“Our MRI imaging partner needed to understand the unique requirements of our
pioneering scientific research. BioClinica’s MRI imaging solution best matched
all of our requirements.”

BioClinica’s Imaging Core Lab uses innovative technology to efficiently
acquire, process, and read medical images. With more than 22 years of
world-wide experience, the team brings the scientific knowledge to make that
technology work for sponsors of any size. With a highly-regarded medical
affairs team and deep roster of collaborative consultants, BioClinica provides
the imaging expertise necessary to ensure the highest quality clinical trial

"BioClinica is clearly a technology leader for clinical trial applications,”
said Peter Benton, BioClinica's eClinical Solutions President. “While great
technology is essential, our business model also offers a fresh approach for
clinical trial support -- one that makes it faster and more cost-efficient
than other alternatives, whether the sponsor is large or small. Combined with
our global reach, experience and customer support, we believe no other
solution matches BioClinica for value or performance.”

Follow BioClinica on the Trial Blazers blog at
http://info.bioclinica.com/blog, and on twitter at

About TauRx

TauRx Therapeutics is a clinical stage pharmaceutical company focused on the
discovery of Tau Protein Aggregation Inhibitors and other novel therapies and
diagnostics for the treatment of Alzheimer's disease (AD) and other
neurodegenerative disorders. TauRx is developing drugs to treat the underlying
pathology of AD, to modify or halt disease progression or to prevent it
entirely. TauRx Therapeutics is headquartered in Singapore with primary
research facilities in Aberdeen, Scotland. For more information please visit

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica supports
pharmaceutical and medical device innovation with imaging core lab, internet
image transport, electronic data capture, interactive voice and web response,
clinical trial management and clinical supply chain design and optimization
solutions. BioClinica solutions maximize efficiency and manageability
throughout all phases of the clinical trial process. With over 22 years of
experience and more than 2,500 successful trials to date, BioClinica has
supported the clinical development of many new medicines from early phase
trials through final approval. BioClinica operates state-of-the-art,
regulatory-body-compliant imaging core labs on two continents, and supports
worldwide eClinical and data management services from offices in the United
States, Europe and Asia. For more information, please visit

Certain matters discussed in this press release are “forward-looking
statements” intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995. In
particular, the Company’s statements regarding trends in the marketplace and
potential future results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties, including, but not
limited to, the consummation and the successful integration of current and
proposed acquisitions, the timing of projects due to the variability in size,
scope and duration of projects, estimates and guidance made by management with
respect to the Company’s financial results, backlog, critical accounting
policies, regulatory delays, clinical study results which lead to reductions
or cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Company’s control. The
factors discussed herein and expressed from time to time in the Company’s
filings with the Securities and Exchange Commission could cause actual results
and developments to be materially different from those expressed in or implied
by such statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent events
or circumstance. You should review the Company’s filings, especially risk
factors contained in the Form 10-K and the recent Form 10-Q.


BioClinica, Inc.
Jim Dorsey, 267-757-3040
Trade Media:
Diccicco Battista Communications
Beth Nestlerode, 484-342-3600
Porter, LeVay & Rose, Inc.
Michael Porter, 212-564-4700
Financial Media:
Porter, LeVay & Rose, Inc.
Bill Gordon, 212-564-4700
Press spacebar to pause and continue. Press esc to stop.